ScholarIQanswers from OpenAlex & ORCID
Christian Jackisch
ResearcherPublications, citations & collaboration network
Christian Jackisch is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Christian Jackisch have?
ScholarIQindexed works
Christian Jackisch has 836 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Christian Jackisch have?
ScholarIQcitation count
Christian Jackisch has 41,939 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Christian Jackisch?
ScholarIQh-index
Christian Jackisch has an h-index of 90 in OpenAlex.
What is the i10-index of Christian Jackisch?
ScholarIQi10-index
Christian Jackisch has an i10-index of 262 in OpenAlex.
What is the ORCID of Christian Jackisch?
ScholarIQorcid
The ORCID for Christian Jackisch is on the source record.
What is the OpenAlex record for Christian Jackisch?
ScholarIQopenalex
The OpenAlex for Christian Jackisch is on the source record.
What are the most-cited papers on Christian Jackisch?
ScholarIQmost cited works
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Barbara Ingold Heppner, Karsten E. Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang Schmitt, Jens‐Uwe Blohmer, Thomas Karn, Berit M. Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiß, Arndt Hartmann, Aurelia Noske, Peter A. Fasching, Christian Jackisch, Marion van Mackelenbergh, Hans‐Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M. Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Dan Costa, Hans Tesch, Claus Hanusch, J. Hilfrich, F Khandan, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch